Title |
Effects of Combined Aspirin and Clopidogrel Therapy on Cardiovascular Outcomes: A Systematic Review and Meta-Analysis
|
---|---|
Published in |
PLOS ONE, February 2012
|
DOI | 10.1371/journal.pone.0031642 |
Pubmed ID | |
Authors |
Yu-Hao Zhou, Xin Wei, Jian Lu, Xiao-Fei Ye, Mei-Jing Wu, Jin-Fang Xu, Ying-Yi Qin, Jia He |
Abstract |
Aspirin and clopidogrel monotherapies are effective treatments for preventing vascular disease. However, new evidence has emerged regarding the use of combined aspirin and clopidogrel therapy to prevent cardiovascular events. We therefore performed a comprehensive systematic review and meta-analysis to evaluate the benefits and harms of combined aspirin and clopidogrel therapy on major cardiovascular outcomes. |
X Demographics
The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
Spain | 2 | 40% |
France | 1 | 20% |
Unknown | 2 | 40% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 3 | 60% |
Practitioners (doctors, other healthcare professionals) | 1 | 20% |
Scientists | 1 | 20% |
Mendeley readers
The data shown below were compiled from readership statistics for 42 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Indonesia | 1 | 2% |
Colombia | 1 | 2% |
United States | 1 | 2% |
Unknown | 39 | 93% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 10 | 24% |
Student > Master | 7 | 17% |
Other | 4 | 10% |
Researcher | 4 | 10% |
Professor | 3 | 7% |
Other | 8 | 19% |
Unknown | 6 | 14% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 18 | 43% |
Pharmacology, Toxicology and Pharmaceutical Science | 4 | 10% |
Chemistry | 2 | 5% |
Agricultural and Biological Sciences | 2 | 5% |
Environmental Science | 1 | 2% |
Other | 7 | 17% |
Unknown | 8 | 19% |